Antigen presentation on artificial acellular substrates: modular systems for flexible, adaptable immunotherapy

Bibliography

• Finn OJ. Cancer immunology. N Engl J Med 2008;358:2704-15
   PubMed Web of Science ®Google Scholar
• Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106
   PubMed Web of Science ®Google Scholar
• June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007;117:1466-76
   PubMed Web of Science ®Google Scholar
• Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006;6:204-16
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299-308
   PubMed Web of Science ®Google Scholar
• Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003;3:666-75
   PubMed Web of Science ®Google Scholar
• Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 2005;28:53-62
   PubMed Web of Science ®Google Scholar
• Becker C, Pohla H, Frankenberger B, et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay. Nat Med 2001;7:1159-62
   PubMed Web of Science ®Google Scholar
• Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007;449:419-26
   PubMed Web of Science ®Google Scholar
• Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-80
   PubMed Web of Science ®Google Scholar
• Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008;29:372-83
   PubMed Web of Science ®Google Scholar
• Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007;220:129-50
   PubMed Web of Science ®Google Scholar
• Oelke M, Maus MV, Didiano D, et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 2003;9:619-24
   PubMed Web of Science ®Google Scholar
• Kim JV, Latouche J, Rivière I, Sadelain M. The ABCs of artificial antigen presentation. Nat Biotechnol 2004;22:403-10
   PubMed Web of Science ®Google Scholar
• Oelke M, Krueger C, Giuntoli RL, Schneck JP. Artificial antigen-presenting cells: artificial solutions for real diseases. Trends Mol Med 2005;11:412-20
   PubMed Web of Science ®Google Scholar
• Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002;2:227-38
   PubMed Web of Science ®Google Scholar
• Acuto O, Bartolo VD, Michel F. Tailoring T-cell receptor signals by proximal negative feedback mechanisms. Nat Rev Immunol 2008;8:699-712
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. The carrier potential of liposomes in biology and medicine (first of two parts). N Engl J Med 1976;295:704-10
   PubMed Web of Science ®Google Scholar
• Gregoriadis G. The carrier potential of liposomes in biology and medicine (second of two parts). N Engl J Med 1976;295:765-70
   PubMed Web of Science ®Google Scholar
• Engelhard VH, Strominger JL, Mescher M, Burakoff S. Induction of secondary cytotoxic T lymphocytes by purified HLA-A and HLA-B antigens reconstituted into phospholipid vesicles. Proc Natl Acad Sci USA 1978;75:5688-91
   PubMed Web of Science ®Google Scholar
• Finberg R, Mescher M, Burakoff SJ. The induction of virus-specific cytotoxic T lymphocytes with solubilized viral and membrane proteins. J Exp Med 1978;148:1620-7
   PubMed Web of Science ®Google Scholar
• Herrmann SH, Mescher MF. Lymphocyte recognition of H-2 antigen in liposomes. J Supramolecular Struct Cell Biochem 1981;16:121-31
   PubMedGoogle Scholar
• Weinberger O, Herrmann SH, Greenstein JL, et al. The ability of Ia and H-2Kk-bearing membranes to replace the antigen-presenting cell in an H-2Kk allogeneic cytotoxic T cell response. Eur J Immunol 1985;15:1013-8
   PubMed Web of Science ®Google Scholar
• Prakken B, Wauben M, Genini D, et al. Artificial antigen-presenting cells as a tool to exploit the immune ‘synapse’. Nat Med 2000;6:1406-10
   PubMed Web of Science ®Google Scholar
• Giannoni F, Barnett J, Bi K, et al. Clustering of T cell ligands on artificial APC membranes influences T cell activation and protein kinase C θ translocation to the T cell plasma membrane. J Immunol 2005;174:3204-11
   PubMed Web of Science ®Google Scholar
• Zappasodi R, Nicola MD, Carlo-Stella C, et al. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells. Haematologica 2008;93:1523-34
   PubMed Web of Science ®Google Scholar
• Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70:1-20
   PubMed Web of Science ®Google Scholar
• Casey KA, Mescher MF. IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype. J Immunol 2007;178:7640-8
   PubMed Web of Science ®Google Scholar
• Curtsinger J, Deeths MJ, Pease P, Mescher MF. Artificial cell surface constructs for studying receptor-ligand contributions to lymphocyte activation. J Immunol Methods 1997;209:47-57
   PubMed Web of Science ®Google Scholar
• Curtsinger JM, Lins DC, Mescher MF. CD8+ memory T cells (CD44high, Ly-6C+) are more sensitive than naive cells to (CD44low, Ly-6C–) to TCR/CD8 signaling in response to antigen. J Immunol 1998;160:3236-43
   PubMed Web of Science ®Google Scholar
• Curtsinger JM, Schmidt CS, Mondino A, et al. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol 1999;162:3256-62
   PubMed Web of Science ®Google Scholar
• Curtsinger JM, Lins DC, Mescher MF. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 2003;197:1141-51
   PubMed Web of Science ®Google Scholar
• Curtsinger JM, Valenzuela JO, Agarwal P, et al. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 2005;174:4465-9
   PubMed Web of Science ®Google Scholar
• Curtsinger JM, Lins DC, Johnson CM, Mescher MF. Signal 3 tolerant CD8 T cells degranulate in response to antigen but lack granzyme B to mediate cytolysis. J Immunol 2005;175:4392-9
   PubMed Web of Science ®Google Scholar
• Deeths MJ, Mescher MF. B7-1-dependent co-stimulation results in qualitatively and quantitatively different responses by CD4+ and CD8+ T cells. Eur J Immunol 1997;27:598-608
   PubMed Web of Science ®Google Scholar
• Deeths MJ, Mescher MF. ICAM-1 and B7-1 provide similar but distinct costimulation for CD8+ T cells, while CD4+ T cells are poorly costimulated by ICAM-1. Eur J Immunol 1999;29:45-53
   PubMed Web of Science ®Google Scholar
• Deeths MJ, Kedl RM, Mescher MF. CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation. J Immunol 1999;163:102-10
   PubMed Web of Science ®Google Scholar
• Mescher MF. Surface contact requirements for activation of cytotoxic T lymphocytes. J Immunol 1992;149:2402-5
   PubMed Web of Science ®Google Scholar
• Jiang X, Lu X, Liu R, et al. HLA tetramer based artificial antigen-presenting cells efficiently stimulate CTLs specific for malignant glioma. Clin Cancer Res 2007;13:7329-34
   PubMed Web of Science ®Google Scholar
• Lu X, Jiang X, Liu R, et al. Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response. Cancer Lett 2008;271:129-39
   PubMed Web of Science ®Google Scholar
• Levine BL, Bernstein WB, Connors M, et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol 1997;159:5921-30
   PubMed Web of Science ®Google Scholar
• Levine BL, Cotte J, Small CC, et al. Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother 1998;7:437-48
   PubMedGoogle Scholar
• Levine BL, Mosca JD, Riley JL, et al. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 1996;272:1939-43
   PubMed Web of Science ®Google Scholar
• Maus MV, Riley JL, Kwok WW, et al. HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. Clin Immunol 2003;106:16-22
   PubMed Web of Science ®Google Scholar
• Oelke M, Schneck JP. HLA-Ig-based artificial antigen-presenting cells: setting the terms of engagement. Clin Immunol 2004;110:243-51
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233-9
   PubMed Web of Science ®Google Scholar
• Acquavella N, Kluger H, Rhee J, et al. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. J Immunother 2008;31:569-76
   PubMed Web of Science ®Google Scholar
• Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96
   PubMed Web of Science ®Google Scholar
• Fahmy TM, Fong PM, Goyal A, Saltzman WM. Targeted for drug delivery. Mater Today 2005;8:18-26
   Web of Science ®Google Scholar
• Mohamed F, van der Walle CF. Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J Pharm Sci 2008;97:71-87
   PubMed Web of Science ®Google Scholar
• Pridgen EM, Langer R, Farokhzad OC. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomed 2007;2:669-80
   PubMed Web of Science ®Google Scholar
• Shalaby WSW, Yeh H, Woo E, et al. Absorbable microparticulate cation exchanger for immunotherapeutic delivery. J Biomed Mater Res Part B Appl Biomater 2004;69:173-82
   PubMedGoogle Scholar
• Fahmy TM, Samstein RM, Harness CC, Mark Saltzman W. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 2005;26:5727-36
   PubMed Web of Science ®Google Scholar
• Steenblock ER, Fahmy TM. A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Mol Ther 2008;16:765-72
   PubMed Web of Science ®Google Scholar
• Rogers J, Mescher MF. Augmentation of in vivo cytotoxic T lymphocyte activity and reduction of tumor growth by large multivalent immunogen. J Immunol 1992;149:269-76
   PubMed Web of Science ®Google Scholar
• Mescher MF, Rogers JD. Immunotherapy of established murine tumors with large multivalent immunogen and cyclophosphamide J Immunotherapy Emphasis Tumor Immunol 1996;19:102-12
   PubMed Web of Science ®Google Scholar
• Mitchell MS, Kan-Mitchell J, Morrow PR, et al. Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma. Clin Cancer Res 2004;10:76-83
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15
   PubMed Web of Science ®Google Scholar
• Riddell SR, Walter BA, Gilbert MJ, Greenberg PD. Selective reconstitution of CD8+ cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones. Bone Marrow Transplant 1994;14(Suppl 4):S78-84
   PubMedGoogle Scholar
• Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-44
   PubMed Web of Science ®Google Scholar
• Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-5
   PubMed Web of Science ®Google Scholar
• Brodie SJ, Lewinsohn DA, Patterson BK, et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med 1999;5:34-41
   PubMed Web of Science ®Google Scholar
• Brodie SJ, Patterson BK, Lewinsohn DA, et al. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest 2000;105:1407-17
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4
   PubMed Web of Science ®Google Scholar
• Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002;99:16168-73
   PubMed Web of Science ®Google Scholar
• Goldberg J, Shrikant P, Mescher MF. In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen). J Immunol 2003;170:228-35
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005;115:1616-26
   PubMed Web of Science ®Google Scholar
• Durai M, Krueger C, Ye Z, et al. In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). Cancer Immunol Immunother 2008;58:209-20
   PubMed Web of Science ®Google Scholar
• Levine BL, Bernstein WB, Aronson NE, et al. Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med 2002;8:47-53
   PubMed Web of Science ®Google Scholar
• Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006;103:17372-7
   PubMed Web of Science ®Google Scholar
• Fowler DH, Odom J, Steinberg SM, et al. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006;12:1150-60
   PubMed Web of Science ®Google Scholar
• Laport GG, Levine BL, Stadtmauer EA, et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 2003;102:2004-13
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Bunin N, et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006;107:1325-31
   PubMed Web of Science ®Google Scholar
• Carroll RG, Riley JL, Levine BL, et al. The role of co-stimulation in regulation of chemokine receptor expression and HIV-1 infection in primary T lymphocytes. Semin Immunol 1998;10:195-202
   PubMed Web of Science ®Google Scholar
• Lu X, Humeau L, Slepushkin V, et al. Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. J Gene Med 2004;6:963-73
   PubMed Web of Science ®Google Scholar
• Lu X, Yu Q, Binder GK, et al. Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. J Virol 2004;78:7079-88
   PubMed Web of Science ®Google Scholar
• Powell DJ, Levine BL. Adoptive T-cell therapy for malignant disorders. Haematologica 2008;93:1452-6
   PubMed Web of Science ®Google Scholar
• Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51-81
   PubMed Web of Science ®Google Scholar
• Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. J Chemother 2004;16(Suppl 4):94-7
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003;42:419-36
   PubMed Web of Science ®Google Scholar
• Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003;42:439-62
   PubMed Web of Science ®Google Scholar
• Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007;101:937-49
   PubMed Web of Science ®Google Scholar
• Sledge GW, Miller KD. Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer 2003;39:1668-75
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53:283-318
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313:1485-92
   PubMed Web of Science ®Google Scholar
• Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol 2007;25:243-65
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Khong HT, Antony PA, et al. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol 2005;26:111-7
   PubMed Web of Science ®Google Scholar